Liothyronine Could Block the Programmed Death-Ligand 1 (Pdl1) Activity: An E-Pharmacophore Modeling and Virtual Screening Study Publisher Pubmed



Pourzardosht N^{1, 2} ; Hashemi ZS³ ; Mardsoltani M⁴ ; Jahangiri A⁵ ; Rahbar MR⁶ ; Zakeri A⁷ ; Mirzajani E^{1, 2} ; Khalili S⁷ Show Affiliations
Source: Journal of Receptors and Signal Transduction Published:2022

Abstract

Purpose: The interaction between PD-L1 on tumor cells and the programmed death 1 (PD1) on immune cells helps them to escape the immune system elimination. Therefore, developing therapeutic agents to block this interaction has garnered a lot of attention as a therapeutic approach. In the present study, we have tried to screen for an inhibitory compound to inhibit the interaction between the PD1/PD-L1 molecules. Methods: In this regard, the structure of PD-L1 and its inhibitor were prepared and employed to generate an e-Pharmacophore model. A library of approved compounds was prepared and toxicity analysis using Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) predictor was performed. The built e-Pharmacophore model was validated and used to screen the prepared compound library. Ligand docking and binding energy calculation were performed on the screened ligands. Results: A seven-feature e-Pharmacophore model was generated using the PD-L1 complex. All of the compounds within the library passed the ADMET criteria. Performing the virtual screening, only 79 compounds have survived the criteria to fit four pharmacophoric features. The compound with the highest binding energy was the liothyronine (T3). Conclusion: The ability of T3 in PD1/PD-L1 checkpoint blockade along with its potential in T4 reduction could be a desirable combination in cancer treatment. These abilities of T3 could be used to restore the ability of the immune system to eliminate tumor cells. © 2020 Informa UK Limited, trading as Taylor & Francis Group.